L’Oréal USA & Organovo Team for 3D Printed Human Skin Tissue Research

IMTS

Share this Article

l2You all probably know by now that Organovo (NYSE: ONVO) is leading the charge when it comes to 3D printing organ tissue. They have already brought human liver tissue to market via their exVive3D brand, and have plans to bring kidney tissue to market sometime in 2016.

The human body’s largest, and arguably most important, organ is the the epidermis and dermis, better known as skin. Organovo of course has shown interest in this area as well when it comes to bioprinting, as there are numerous applications in which 3D printed skin could certainly come in handy.l3

Today the company, which seems to be quite busy as of late, announced a Research Collaboration Agreement with one of the world’s largest skincare companies, L’Oréal USA Products, Inc. As a part of this agreement, both firms will contribute significant technology to this collaborative work. Organovo will provide their NovoGen Bioprinter and L’Oréal, their skin cell technology.

The partnership will be broken down into three key phases, of which L’Oréal will have the power of continuing or ending the collaboration at the completion of each phase, depending on whether or not certain specified criteria are met. These phases include ‘development,’ ‘validation,’ and ‘commercial supply.’

For the initial two phases, L’Oréal USA will provide up-front funding for the project, and for the final phase both parties will eventually forge a commercial supply agreement, including customary licensing and royalty terms, should the collaboration make it to this final phase. The financial l1terms of this agreement have not been made public, and Organovo intends on submitting a FOIA Confidential Treatment Request to the SEC requesting that they be permitted to hold back some of the sensitive details as ‘trade secrets.’

The agreement will provide L’Oréal with exclusive rights to the skin tissue that the two companies develop. These rights will remain intact for the purposes of development, testing, manufacturing, evaluation, and sale of non-prescription skincare products as well as nutraceutical supplements. Organovo on the other hand will retain the rights to these tissue models for efficacy testing of prescription drugs, toxicity tests, and the development and testing of therapeutic or surgically transplanted tissues.

A Sample of Organovo's Printed Liver issue

A Sample of Organovo’s Printed Liver issue

There is little doubt that the potential impact this agreement could have on the bottom lines of each company involved could be staggering. It will be interesting to see if this agreement makes it to the final phase, and just what may result from a product standpoint.

Organovo seems to be spreading their wings all over the 3D bioprinting space. As the next year or two go by, they will certainly be an interesting company to follow. Let us know your thoughts on what this collaboration may mean, both for Organovo as a company, and for the general bioprinting industry. Discuss in the Organovo & L’Oréal forum thread on 3DPB.com.

Share this Article


Recent News

3D Printing Financials: Materialise Reports Growth in 2023 with Medical Segment Success

3DPOD Episode 188: Clare Difazio of E3D – Growing the Industry, and Growing With the Industry



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Printing News Unpeeled: Solenoids, Hydrogel Buildings and Missiles

Malgorzata A. Zboinska and others at Chalmers University of Technology and the Wallenberg Wood Science Center have managed to 3D print a hydrogel made of alginate and nano-cellulose. They hope...

Featured Sponsored

3DXTECH Launches “Pellet to Part” Program for 3D Printing Materials

Always looking to shake up the material extrusion segment of 3D printing, Michigan-based 3DXTECH has introduced a novel initiative named the “Pellet to Part” program. To further drive collaboration with...

Interview: NAGASE Facilitates AM Adoption with EMPOWR3D 3D Printing Brand

The additive manufacturing (AM) market is entering a new phase in which large companies from outside of the segment have entered and begun consolidating. In reality, this trend has been...

Featured

Printing Money Episode 15: 3D Printing Markets & Deals, with AM Research and AMPOWER

Printing Money returns with Episode 15! This month, NewCap Partners‘ Danny Piper is joined by Scott Dunham, Executive Vice President of Research at Additive Manufacturing (AM) Research, and Matthias Schmidt-Lehr,...